Strain Data Sheet

RBRC02344

Strain Information

Image
BRC No.RBRC02344
TypeTargeted MutationCartagena
SpeciesMus musculus
Strain nameFVB.129P2-Nf2<tm2Gth>
Former Common nameNf2flox2 (FVB)
H-2 Haplotype
ES Cell line
Background strainFVB/NJcl
Appearancealbino [A/A B/B c/c D/D P/P]
Strain development開発者／機関：INSERM U674開発年：1998年FVB/Nに10代backcrossした後、intercrossにて維持。
Strain descriptionNf2 (Schwannomin)のexon2の両側にloxPが挿入されているマウス。
Colony maintenance兄妹交配
ReferencesGenes Dev., 14, 1617-1630 (2000). 10887156

Health Report

Examination Date / Room / Rack2024/02/26Room:4-BRack:K
2023/11/27Room:4-BRack:K
2023/08/28Room:4-BRack:K
2023/05/29Room:4-BRack:K
2023/02/27Room:4-BRack:K
2022/11/29Room:4-BRack:K
2022/08/29Room:4-BRack:K
2022/05/31Room:4-BRack:K

Gene

Gene info
Gene symbolGene nameChr.Allele symbolAllele nameCommon namesPromoter
Nf2neurofibromatosis 211Nf2<tm2Gth>targeted mutation 2, Gilles Thomasmerlin, moesin-ezrin-radixin-like protein, schwannomin

Gene symbolGene nameChr.Allele symbolAllele nameCommon namesPromoter
loxPphage P1 loxP11loxP

Gene symbolGene nameChr.Allele symbolAllele nameCommon namesPromoter
loxPphage P1 loxP11loxP

Ordering Information

供与核酸phage P1 loxP sites, mouse Nf2 genomic DNA
Research applicationCre/loxP system
提供条件条件を付加する。
研究成果の公表にあたって寄託者の指定する文献を引用する。Genes Dev., 14, 1617-1630 (2000).
研究成果の公表にあたって謝辞の表明を必要とする。
RECIPIENT shall keep DEPOSITOR apprised of any results obtained from the BIOLOGICAL RESOURCE in the course of the research, as soon as they are available. Moreover, if the research results in a potential invention or a substance that may have potential commercial value (hereinafter referred as to the "Invention") RECIPIENT will promptly disclose this Invention to DEPOSITOR with samples thereof for DEPOSITOR's internal use.
RECIPIENT and DEPOSITOR will consult together and agree about the possibility of filing one or more patent application to Invention conceived by one or more employees of Recipients that directly arise out of the research. The Parties will negotiate in good faith the conditions of such patent application according to each party's inventiveness contribution in the Invention.
In case of such Invention, patentable or not, reduced in practice or developed in the course of the research that could not have been obtained, reduced to practice or developed but from using the Material and/or Confidential Information, RECIPIENT and DEPOSITOR shall confer with one another as regards licensing and commercialization of such Invention to negotiate in good faith the terms of an institutional agreement as regards said matters.
DepositorMarco Giovannini（INSERM）
Strain Status生体のアイコン生体
凍結胚のアイコン凍結胚
Strain Availability凍結胚を1ヶ月以内に提供可能
生体マウスを1~3ヶ月以内に提供可能
Additional Info.Necessary documents for ordering:
  1. Order form (Japanese / English)
  2. Category I MTA: MTA for distribution with RIKEN BRC (Japanese / English)
  3. Acceptance of responsibility for living modified organism (Japanese / English)

Genotyping protocol -PCR-

BRC mice in Publications

Ahmad I, Fernando A, Gurgel R, Jason Clark J, Xu L, Hansen MR.
Merlin status regulates p75(NTR) expression and apoptotic signaling in Schwann cells following nerve injury.
Neurobiol Dis 82 114-122(2015) 26057084